Swiss biotech company Santhera Pharmaceuticals AG is looking at an initial public offering among several other options to finance its drug development pipeline, Chief Executive Klaus Schollmeier said.
Swiss biotech company Santhera Pharmaceuticals AG is looking at an initial public offering among several other options to finance its drug development pipeline, Chief Executive Klaus Schollmeier said.